Parameningeal Rhabdomyosarcoma: Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 Study: Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 Study
Uloženo v:
| Název: | Parameningeal Rhabdomyosarcoma: Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 Study: Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 Study |
|---|---|
| Autoři: | Reineke A. Schoot, Pieter Taselaar, Giovanni Scarzello, Frederic Kolb, Beatrice Coppadoro, Simone ter Horst, Henry Mandeville, Andrea Ferrari, Raquel Hladun, Sylvie Helfre, Sima Ferman, Anna Kelsey, Marinka L. F. Hol, Christine Devalck, Myriam Ben‐Arush, Daniel Orbach, Julia Chisholm, Meriel Jenney, Veronique Minard‐Colin, Gianni Bisogno, Johannes H. M. Merks |
| Přispěvatelé: | Institut Català de la Salut, [Schoot RA, Taselaar P] Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. [Scarzello G] Veneto Institute of Oncology IOV—IRCCS, Padua, Italy. [Kolb F] Plastic and Reconstructive Surgery, UC San Diego, University of California, San Diego, California, USA. [Coppadoro B] Department of Women's and Children's Health, Hematology Oncology Division, University of Padua, Padua, Italy. [Horst ST] Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands. [Hladun R] Servei d’Hematologia i Oncologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus, MS Radiologie, MS KNO, Onderzoek Beeld, Mandeville, Henry |
| Zdroj: | Head Neck Scientia Scientia. Dipòsit d'Informació Digital del Departament de Salut instname |
| Informace o vydavateli: | Wiley, 2024. |
| Rok vydání: | 2024 |
| Témata: | NAMED GROUPS::Persons::Age Groups::Child, head and neck, parameningeal, pediatric, prognostic risk factors, rhabdomyosarcoma, Other subheadings::Other subheadings::/therapy, DENOMINACIONES DE GRUPOS::personas::Grupos de Edad::niño, Tumors de parts toves - Tractament, 03 medical and health sciences, 0302 clinical medicine, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico, Músculs - Càncer - Prognosi, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de tejido conjuntivo y de tejidos blandos::neoplasias de tejido muscular::miosarcoma::rabdomiosarcoma, DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Neoplasms, Muscle Tissue::Myosarcoma::Rhabdomyosarcoma, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema nervioso::neoplasias del sistema nervioso central::neoplasias meníngeas, Otros calificadores::Otros calificadores::/terapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, Otorhinolaryngology, DISEASES::Neoplasms::Neoplasms by Site::Nervous System Neoplasms::Central Nervous System Neoplasms::Meningeal Neoplasms, Avaluació de resultats (Assistència sanitària), ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis, Original Article, Infants |
| Popis: | BackgroundParameningeal (PM) site is an unfavorable characteristic in rhabdomyosarcoma (RMS). We described the treatment and outcome for patients with PM RMS and investigated the prognostic value of risk factors. We scored PM site by originating site and by highest risk extension.MethodsPatients with PM RMS were treated within the European pediatric Soft tissue sarcoma Study Group (EpSSG) RMS 2005 study with risk‐adapted, multi‐modal treatment.ResultsThree‐hundred‐eighty‐one patients with PM RMS were included. Radiotherapy was administered in 359 patients (77 with surgery). After a median follow‐up of 75 months, 5‐year event‐free survival was 60% (95% confidence interval (CI) 55%–65%), 5‐year overall survival was 65% (95% CI 60%–70%).ConclusionsThe outcome for patients with PM RMS has not improved in comparison to previous historical studies, despite the more rigorous application of radiotherapy (94% of patients). Signs of meningeal involvement, PM site, and age at diagnosis remained prognostic risk factors.Trial RegistrationEudraCT number 2005‐000217‐35 |
| Druh dokumentu: | Article Other literature type |
| Popis souboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 1097-0347 1043-3074 |
| DOI: | 10.1002/hed.27994 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/39545397 http://hdl.handle.net/11351/12713 https://dspace.library.uu.nl/handle/1874/459224 https://pure.amsterdamumc.nl/en/publications/b34c28f6-9c6a-4809-a9d4-2fa95aff5d1b https://doi.org/10.1002/hed.27994 https://hdl.handle.net/11577/3553659 https://doi.org/10.1002/hed.27994 |
| Rights: | CC BY NC ND URL: http://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| Přístupové číslo: | edsair.doi.dedup.....485e81b383a45fe3a4c759eb85b45856 |
| Databáze: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | BackgroundParameningeal (PM) site is an unfavorable characteristic in rhabdomyosarcoma (RMS). We described the treatment and outcome for patients with PM RMS and investigated the prognostic value of risk factors. We scored PM site by originating site and by highest risk extension.MethodsPatients with PM RMS were treated within the European pediatric Soft tissue sarcoma Study Group (EpSSG) RMS 2005 study with risk‐adapted, multi‐modal treatment.ResultsThree‐hundred‐eighty‐one patients with PM RMS were included. Radiotherapy was administered in 359 patients (77 with surgery). After a median follow‐up of 75 months, 5‐year event‐free survival was 60% (95% confidence interval (CI) 55%–65%), 5‐year overall survival was 65% (95% CI 60%–70%).ConclusionsThe outcome for patients with PM RMS has not improved in comparison to previous historical studies, despite the more rigorous application of radiotherapy (94% of patients). Signs of meningeal involvement, PM site, and age at diagnosis remained prognostic risk factors.Trial RegistrationEudraCT number 2005‐000217‐35 |
|---|---|
| ISSN: | 10970347 10433074 |
| DOI: | 10.1002/hed.27994 |